An overview of different methods of myocardial protection currently employed peri-transplantation

Abstract

Myocardial protection is integral to the functioning of hearts in day to day cardiac surgery. However, due to the longer ischaemic times, it becomes pivotal in the management of organs during transplantation. There are many different strategies employed to ensure diligent and judicious myocardial protection during donor management, transportation of the heart and the post-operative period. Given the limited supply of organs and the increasing waiting lists for heart transplants worldwide, it has become an area of renewed interest with many innovations and inventions using the principles of basic sciences to improve outcomes of transplanted hearts. The heart procurement process encompasses several of the different myocardial protection strategies in tandem to provide the greatest benefit to the recipients. This review looks at the different modalities employed, which include different types of cardioplegia, the role of biomarkers, the cutting-edge novel therapies, hormonal therapies and ischaemic conditioning strategies.

Keywords

Myocardial protection / cardiac surgery / cardiac transplantation

References

[1] Ravishankar V.March of cardiac surgery through the decades..Med J Armed Forces India2014;70:3-4 PMCID:PMC3946512

[2] Konstantinov IE.At the cutting edge of the impossible: a tribute to Vladimir P. Demikhov..Tex Heart Inst J2009;36:453-8 PMCID:PMC2763473

[3] Lower RR,Hurley EJ,Cohn RB.Successful homotransplantation of the canine heart after anoxic preservation for seven hours..Am J Surg1962;104:302-6

[4] Dong EJr,Lower RR.Performance of the heart two years after autotransplantation..Surgery1964;56:270-4

[5] Shumway NE.Special problems in transplantation of the heart..Ann N Y Acad Sci1964;120:773-7

[6] Barnard CN.The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town..S Afr Med J1967;41:1271-4

[7] Lansman SL,Griepp RB.The history of heart and heart-lung transplantation..Cardiovasc Clin1990;20:3-19

[8] Stehlik J,Kucheryavaya AY,Christie JD,Dobbels F,Hertz MI.The registry of the international society for heart and lung transplantation: twenty-seventh official adult heart transplant report--2010..J Heart Lung Transplant2010;29:1089-103

[9] Lietz K.Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990 to 2005..J Am Coll Cardiol2007;50:1282-90

[10] Abuanzeh R,Dimarakis I,Machaal A,Venkateswaran RV.Early donor management increases the retrieval rate of hearts for transplantation in marginal donors..Eur J Cardiothorac Surg2015;47:72-7; discussion 77

[11] Ringer S.A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart..J Physiol1883;4:29-42 PMCID:PMC1484842

[12] Tyers GF,Niebauer IM,Waldhausen JA.The mechanism of myocardial damage following potassium citrate (Melrose) cardioplegia..Surgery1975;78:45-53

[13] Maathuis MH,Ploeg RJ.Perspectives in organ preservation..Transplantation2007;83:1289-98

[14] tHart NA, Leuvenink HGD, Ploeg RJ. New solutions in organ preservation. Available from: http://www.sciencedirect.com/science/article/pii/S0955470X02800027. [Last accessed on 20 Oct 2017]

[15] Shumway NE.Topical cardiac hypothermia for extended periods of anoxic arrest..Surg Forum1960;10:563-6

[16] Blaisdell FW.The mechanism of paraplegia after temporary thoracic aortic occlusion and its relationship to spinal fluid pressure..Surgery1962;51:351-5

[17] Kay EB,Nogueira C.Direct coronary artery perfusion for aortic valve surgery; report of technique..J Am Med Assoc1958;168:1767-8

[18] Senning A.Ventricular fibrillation during hypothermia, used as a method to facilitate intracardiac operations..Acta Chir Scand1955;109:303-9

[19] Bretschneider HJ,Knoll D,Nordbeck H.Myocardial resistance and tolerance to ischemia: physiological and biochemical basis..J Cardiovasc Surg (Torino)1975;16:241-60

[20] Hearse DJ,Braimbridge MV.Cellular protection during myocardial ischemia: the development and characterization of a procedure for the induction of reversible ischaemic arrest..Circulation1976;54:193-202

[21] Buckberg GD.Recent progress in myocardial protection during cardiac operations..Cardiovasc Clin1987;17:291-319

[22] Hearse DJ,Nayler WG,Border D.Ultrastructural damage associated with reoxygenation of the anoxic myocardium..J Mol Cell Cardiol1975;7:315-24

[23] Chambers DJ.Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion..Pharmacol Ther2010;127:41-52

[24] Reichenspurner H,Uberfuhr P,Schlüter A,Klövekorn WP,Hetzer R.Myocardial preservation using HTK solution for heart transplantation. A multicenter study..Eur J Cardiothorac Surg1993;7:414-9

[25] Sung SY,Song JY,Kao CH,Lin YC,Tsai CS.Myocardial protection in donor heart preservation: a comparison between Bretschneider's histidine-tryptophan-ketoglutarate solution and cold blood cardioplegia..Transplant Proc2014;46:1077-81

[26] Minami K,Böthig D,Wlost S,Körfer R.Creatine kinase and troponin after myocardial preservation using HTK solution (Custoidol) for clinical heart transplantation..J Heart Lung Transplant2003;22:192-4

[27] Larsen M,Kennington S,Sheppard J,Unsworth-White J.Mannitol in cardioplegia as an oxygen free radical scavenger measured by malondialdehyde..Perfusion2002;17:51-5

[28] Cordell AR.Milestones in the development of cardioplegia..Ann Thorac Surg1995;60:793-6

[29] Chambers DJ,Braimbridge MV,Manzanera G,Jupp RA,Slavin B.Clinical validation of St. Thomas' hospital cardioplegic solution No. 2 (Plegisol)..Eur J Cardiothorac Surg1989;3:346-52

[30] Luciani GB,Montalbano G,Forni A,Mazzucco A.Blood versus crystalloid cardioplegia for myocardial protection of donor hearts during transplantation: a prospective, randomized clinical trial..J Thorac Cardiovasc Surg1999;118:787-95

[31] Luciani GB,Rigatelli G,Cardaioli P,Faggian G.Myocardial protection in heart transplantation using blood cardioplegia: 12-year outcome of a prospective randomized trial..J Heart Lung Transplant2011;30:29-36

[32] Collins GM,Clunie GJ.Kidney preservation for transportation. Experimental analysis of optimal perfusate composition..Br J Surg1972;59:187-9

[33] Andrews PM.Improving Euro-Collins flushing solution's ability to protect kidneys from normothermic ischemia..Miner Electrolyte Metab1985;11:309-13

[34] Hendry PJ,Keon WJ.A comparison of intracellular solutions for donor heart preservation..J Thorac Cardiovasc Surg1993;105:667-73

[35] James H.Southard MDa, Folkert O. Belzer MD. ORGAN PRESERVATION..Ann Rev Med1995;46:235-47

[36] Ploeg RJ,McAnulty JF,Belzer FO.Successful 72-hour cold storage of dog kidneys with UW solution..Transplantation1988;46:191-6

[37] Todo S,Yanaga K,Gordon RD.Extended preservation of human liver grafts with UW solution..JAMA1989;261:711-4 PMCID:PMC2954660

[38] Jamieson NV,Lindell S,Moen J,Wight DG,Belzer FO.Preservation of the canine liver for 24-48 hours using simple cold storage with UW solution..Transplantation1988;46:517-22

[39] Kozlova I,Roomans GM.Preservation of mouse liver tissue during cold storage in experimental solutions assessed by x-ray microanalysis..Liver Transpl2003;9:268-78

[40] Vreugdenhil PK,Southard JH.Effect of cold storage on tissue and cellular glutathione..Cryobiology1991;28:143-9

[41] Biguzas M,Howden BO,Walls K,Marshall VC.Evaluation of UW solution in rat kidney preservation. II. The effect of pharmacological additives..Transplantation1990;49:1051-5

[42] Kur F,Meiser B,Reichart B.Clinical heart transplantation with extended preservation time (> 5 hours): experience with University of Wisconsin solution..Transplant Proc2009;41:2247-9

[43] Jeevanandam V,Auteri JS,Fong J,Marboe CC,Smith CR.University of Wisconsin solution versus crystalloid cardioplegia for human donor heart preservation. A randomized blinded prospective clinical trial..J Thorac Cardiovasc Surg1992;103:194-8; discussion 198-9

[44] Mankad P,Yacoub M.Endothelial dysfunction caused by University of Wisconsin preservation solution in the rat heart. The importance of temperature..J Thorac Cardiovasc Surg1992;104:1618-24

[45] Saitoh Y,Ku K,Nosaka S,Nakayama K.Heart preservation in HTK solution: role of coronary vasculature in recovery of cardiac function..Ann Thorac Surg2000;69:107-12

[46] De Santo LS,Romano G,Maiello C,Marra C,Scardone M.High-risk heart grafts: effective preservation with Celsior solution..Heart Vessels2006;21:89-94

[47] Careaga G,Téllez S,Borrayo G.Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients..Arch Med Res2001;32:296-9

[48] Lee KC,Chuang YC,Yang HS,Lee YT,Chen IC.Combined St. Thomas and histidine-tryptophan-ketoglutarat solutions for myocardial preservation in heart transplantation patients..Transplant Proc2012;44:886-9

[49] Careaga G,Téllez S,Borrayo G.Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients..Arch Med Res2001;32:296-9

[50] Vega JD,Jeevanandam V,McCurry KR,Stringham JC,Frazier OH,Staples ED,Emery RW,Carrier M,Aziz S,Pham SM.A multicenter, randomized, controlled trial of Celsior for flush and hypothermic storage of cardiac allografts..Ann Thorac Surg2001;71:1442-7

[51] Wieselthaler GM,Konetschny R,Mallinger R,Griessmacher A,Wolner E.Improved graft function using a new myocardial preservation solution: Celsior. Preliminary data from a randomized prospective study..Transplant Proc1999;31:2067-8

[52] Cannata A,Colombo T,Taglieri C,Merlanti B,Martinelli L.Does the cardioplegic solution have an effect on early outcomes following heart transplantation?.Eur J Cardiothorac Surg2012;41:e48-52; discussion e52-3

[53] George TJ,Beaty CA,Conte JV.A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischaemic necrosis than Celsior in early cardiac allograft biopsy specimens..J Heart Lung Transplant2012;31:410-8 PMCID:PMC3307820

[54] George TJ,Baumgartner WA,Conte JV.Organ storage with University of Wisconsin solution is associated with improved outcomes after orthotopic heart transplantation..J Heart Lung Transplant2011;30:1033-43

[55] Kofler S,Kaczmarek I,Müller T,Steinbeck G,Reichart B.Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center..Transpl Int2009;22:1140-50

[56] Garlicki M,Rudziński P,Sadowski J,Pietrzyk E,Drukała J.Myocardial protection for transplantation..Transplant Proc1999;31:2079-83

[57] Lee S,Kawamura T,Billiar TR,Toyoda Y.Histidine-tryptophan-ketoglutarate or celsior: which is more suitable for cold preservation for cardiac grafts from older donors?.Ann Thorac Surg2011;91:755-63

[58] Ackemann J,Mory M,Gebhard MM.Celsior versus custodiol: early postischemic recovery after cardioplegia and ischemia at 5 degrees C..Ann Thorac Surg2002;74:522-9

[59] Lurati Buse GA,Grapow M,Seeberger M.The prognostic value of troponin release after adult cardiac surgery - a meta-analysis..Eur J Cardiothorac Surg2010;37:399-406

[60] De Santo LS,Romano G,Buonocore M,Della Corte A,Nappi G.Perioperative myocardial injury after adult heart transplant: determinants and prognostic value..PLoS One2015;10:e0120813 PMCID:PMC4420471

[61] Gross GJ,Warltier DC.Mechanisms of postischemic contractile dysfunction..Ann Thorac Surg1999;68:1898-904

[62] Dengler TJ,Klingenberg R,Schnabel PA.Biomarkers after heart transplantation: nongenomic..Heart Fail Clin2007;3:69-81

[63] Masuda M,Tomita H,Nishida T,Yasui H.Off-pump CABG attenuates myocardial enzyme leakage but not postoperative brain natriuretic peptide secretion..Ann Thorac Cardiovasc Surg2002;8:139-44

[64] Hajjar L, Galas F, Grande S, Campos M, Silva R, Marques A, Leao W, Auler Jr J. Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with cardiovascular death, postoperative cardiac, renal and pulmonary dysfunction. Available from: https://ccforum.biomedcentral.com/track/pdf/10.1186/cc6665. [Last accessed on 20 Oct 2017]

[65] McIlroy DR,Roubos N.Brain natriuretic peptide (BNP) as a biomarker of myocardial ischemia-reperfusion injury in cardiac transplantation..J Cardiothorac Vasc Anesth2010;24:939-45

[66] Cavarretta E.MicroRNAs in coronary heart disease: ready to enter the clinical arena?.Biomed Res Int2016;2016:2150763

[67] Wang E,Zhao Q,Huang J,Zhang H,Zheng Z.Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation..J Cardiothorac Surg2013;8:165 PMCID:PMC3716980

[68] Russo MJ,Sorabella RA,Garrido M,George I,Mosca RS,Ascheim DD,Stewart AS,Naka Y.The effect of ischaemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for organ sharing database..J Thorac Cardiovasc Surg2007;133:554-9

[69] Goldsmith KA,Gooi JH,Jenkins DP,Tsui SS.Life-years gained by reducing donor heart ischaemic times..Transplantation2009;87:243-8

[70] Hassanein WH,Tyrrell TA,Crittenden MD,Khuri SF.Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function..J Thorac Cardiovasc Surg1998;116:821-30

[71] Messer S,Tsui S.Normothermic donor heart perfusion: current clinical experience and the future..Transpl Int2015;28:634-42

[72] Tenderich G, El-Banayosy A, Rosengard B, Tsui S, Wallwork J, Hetzer R, Koerfer R, Hassanein W. 10: Prospective multi-center European trial to evaluate the safety and performance of the Organ Care System for heart transplants (PROTECT). Available from: http://www.jhltonline.org/article/S1053-2498(06)00824-2/fulltext. [Last accessed on 20 Oct 2017]

[73] McCurry K, Jeevanandam V, Mihaljevic T, Couper G, Elanwar M, Saleh H, Ardehali A. 294: Prospective Multi-center safety and effectiveness evaluation of the Organ Care System device for cardiac use (PROCEED). Available from: http://www.jhltonline.org/article/S1053-2498(07)01142-4/abstract. [Last accessed on 20 Oct 2017]

[74] Hamed A,Huber J,Poggio EC.19: Serum lactate is a highly sensitive and specific predictor of post cardiac transplant outcomes using the Organ Care System..J Heart Lung Transplant2009;28:S71

[75] Ardehali A,Deng M,Hsich E,Mancini D,Zucker M,Padera R.Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial..Lancet2015;385:2577-84

[76] Daemen JW,Wijnen RM,Heineman E.Nonheart-beating donors: the Maastricht experience..Clin Transpl1994;303-16

[77] Iyer A,Doyle A,Cropper JR,Dinale A,Jabbour A,Jansz PC,Harvey RP,Dhital KK.Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors..Am J Transplant2015;15:371-80

[78] Dhital KK,Connellan M,Gao L,Hicks M,Soto C,Cartwright B,Granger E,Jabbour A,Keogh A,Graham R,Macdonald P.Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series..Lancet2015;385:2585-91

[79] Boucek MM,Dunn SM,Edwards L,Campbell D.Pediatric heart transplantation after declaration of cardiocirculatory death..N Engl J Med2008;359:709-14

[80] Walsh F. Europe's first non-beating heart transplant. Available from: http://www.bbc.com/news/health-32056350. [Last accessed on 20 Oct 2017]

[81] Truog RD,Halpern SD.The dead-donor rule and the future of organ donation..N Engl J Med2013;369:1287-9

[82] Ullah S,Watkins B.Cardiac organ donor management..Perfusion2006;21:93-8

[83] Cuisinier A,Payen JF,Walther G.Myocardial function at the early phase of traumatic brain injury: a prospective controlled study..Scand J Trauma Resusc Emerg Med2016;24:129 PMCID:PMC5084439

[84] Novitzky D,Cooper DK,Min KW.Ultrastructure changes associated with brain death in the human donor heart..Transpl Int1997;10:24-32

[85] Kilic A,Sai-Sudhakar CB,Whitson BA.Donor selection in heart transplantation..J Thorac Dis2014;6:1097-104 PMCID:PMC4133543

[86] Lee H,Sung K,Chung CR,Suh GY.The use of extracorporeal circulation in suspected brain dead organ donors with cardiopulmonary collapse..J Korean Med Sci2015;30:1911-4 PMCID:PMC4689839

[87] Cooper LB,Williams M,Croezen D,Rogers JG.Thyroid hormone use during cardiac transplant organ procurement..Clin Transplant2016;30:1578-83

[88] Novitzky D,Rosendale JD.Hormonal therapy of the brain-dead organ donor: experimental and clinical studies..Transplantation2006;82:1396-401

[89] Novitzky D,Wicomb W.Hormonal therapy to the brain-dead potential organ donor: the misnomer of the "Papworth cocktail"..Transplantation2008;86:1479

[90] Wheeldon DR,Oduro A,Large SR.Transforming the "unacceptable" donor: outcomes from the adoption of a standardized donor management technique..J Heart Lung Transplant1995;14:734-42

[91] Wojda TR,Yandle KP,Axelband J,Thomas PG,Hoff WS.Keys to successful organ procurement: an experience-based review of clinical practices at a high-performing health-care organization..Int J Crit Illn Inj Sci2017;7:91-100 PMCID:PMC5479082

[92] Hahnenkamp K,Wolters H,Schneider D.Organ-protective intensive care in organ donors..Dtsch Arztebl Int2016;113:552-8 PMCID:PMC5015577

[93] Nicolas-Robin A,Amour J,Riou B.Hydrocortisone supplementation enhances hemodynamic stability in brain-dead patients..Anesthesiology2010;112:1204-10

[94] Novitzky D,Muchmore JS.Pituitary function in brain-dead patients..Transplantation1989;48:1078-9

[95] Barnes PJ.Beta-adrenergic receptors and their regulation..Am J Respir Crit Care Med1995;152:838-60

[96] Clemente G,Colomba D,Renda C,Maida C,Pinto A.When sepsis affects the heart: a case report and literature review..World J Clin Cases2015;3:743-50 PMCID:PMC4539415

[97] McLean KM,Pandalai PK,Bulcao CF,Akhter SA.Glucocorticoids alter the balance between pro- and anti-inflammatory mediators in the myocardium in a porcine model of brain death..J Heart Lung Transplant2007;26:78-84

[98] Guglin M.How to increase the utilization of donor hearts?.Heart Fail Rev2015;20:95-105

[99] Pandit RA,Gurav SK,Karnath S,Abhram B,Gupta A,Patil V,Dixit S,Todi S.Management of potential organ donor: Indian society of critical care medicine: position statement..Indian J Crit Care Med2017;21:303-16 PMCID:PMC5455024

[100] Pinsard M,Mertes PM,Zitouni S,Pierrot M,Menguy E,Escaravage L,Vignon P.Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study..Crit Care2014;18:R158 PMCID:PMC4220083

[101] Dimopoulou I,Anthi A,Ilias I,Charalambidis C,Orfanos S,Thalassinos N.High prevalence of decreased cortisol reserve in brain-dead potential organ donors..Crit Care Med2003;31:1113-7

[102] Dhar R,Coleman J,Kappel D,Wright R.Comparison of high- and low-dose corticosteroid regimens for organ donor management..J Crit Care2013;28:111e1-7

[103] Novitzky D,Chaffin JS,DeBault LE.Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient..Transplantation1990;49:311-6

[104] Chen YF,Chen J,Said S,Gerdes AM.Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats..J Mol Cell Cardiol2008;44:180-7 PMCID:PMC2235814

[105] Jeevanandam V,Regillo T,Eldridge C.Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy..J Heart Lung Transplant1994;13:681-7; discussion 685-7

[106] Novitzky D,Sun Q,Cooper DK.Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis..Transplantation2014;98:1119-27

[107] Macdonald PS,Bhonagiri D,O'Callaghan G,Watson A.A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors..Crit Care Med2012;40:1635-44

[108] Venkateswaran RV,Quinn DW,Wilson IC,Thompson RD,Bonser RS.The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial..Eur Heart J2009;30:1771-80

[109] Novitzky D,Cooper DK.Improved cardiac function following hormonal therapy in brain dead pigs: relevance to organ donation..Cryobiology1987;24:1-10

[110] Votapka TV,Pennington DG,Swartz MT.Effect of triiodothyronine on graft function in a model of heart transplantation..Ann Thorac Surg1996;62:78-82

[111] Hing AJ,Garlick SR,Kesteven SH,Wilson MK,Macdonald PS.The effects of hormone resuscitation on cardiac function and hemodynamics in a porcine brain-dead organ donor model..Am J Transplant2007;7:809-17

[112] Zimmerman EA,Hou-Yu A.Vasopressinergic and oxytocinergic pathways in the central nervous system..Fed Proc1984;43:91-6

[113] Yoshioka T,Uenishi M,Sadamitsu D,Sugimoto T.Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study..Neurosurgery1986;18:565-7

[114] Blaine EM,Frolicher D,Bluth LL.Vasopressin supplementation in a porcine model of brain-dead potential organ donors..Transplantation1984;38:459-64

[115] Rostron AJ,Cork DM,Kirby JA.Hemodynamic resuscitation with arginine vasopressin reduces lung injury after brain death in the transplant donor..Transplantation2008;85:597-606

[116] Chen JM,Spanier TB,John R,Oz MC.Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors..Circulation1999;100:II244-6

[117] Pennefather SH,Mantle D.Use of low dose arginine vasopressin to support brain-dead organ donors..Transplantation1995;59:58-62

[118] Kinoshita Y,Yoshioka T,Sugimoto T.Long-term renal preservation after brain death maintained with vasopressin and epinephrine..Transpl Int1990;3:15-8

[119] Papadopoulos G,Siminelakis S,Baikoussis NG.Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study..J Cardiothorac Surg2010;5:17 PMCID:PMC2855562

[120] Calva E,Nú-ez R,Bisteni A.Mitochondrial biochemical changes and glucose-KCl-insulin solution in cardiac infarct..Am J Physiol1966;211:71-6

[121] Opie LH,Owen P.Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon..Circulation1975;52:49-57

[122] Sodi-pallares D,Fishleder BL,Medrano GA,De Micheli A.Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report..Am J Cardiol1962;9:166-81

[123] Fath-Ordoubadi F.Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials..Circulation1997;96:1152-6

[124] Sun SC,Masetti P,Laurence RG,Cohn LH.Improved recovery of heart transplants by combined use of oxygen-derived free radical scavengers and energy enhancement..J Thorac Cardiovasc Surg1992;104:830-7

[125] Pilati CF,Maron MB.Factors involved in left ventricular dysfunction after massive sympathetic activation..Am J Physiol1992;263:H784-91

[126] Szabo G,Bahrle S,Hagl S.Brain death impairs coronary endothelial function..Transplantation2002;73:1846-8

[127] Nicolas-Robin A,Ibanez-Esteve C,Riou B.Effect of glucose-insulin-potassium in severe acute heart failure after brain death..Crit Care Med2008;36:2740-5

[128] Heusch G,Rahimtoola SH.Myocardial hibernation: a delicate balance..Am J Physiol Heart Circ Physiol2005;288:H984-99

[129] Stanley AWJr,Russell RO,Mantle JA,McDaniel HG.Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease. Studies on myocardial carbohydrate, lipid and oxygen arterial-coronary sinus differences in patients with coronary artery disease..Am J Cardiol1975;36:929-37

[130] Taegtmeyer H,Doenst T.Substrate metabolism as a determinant for postischemic functional recovery of the heart..Am J Cardiol1997;80:A3-10

[131] Cottin Y,Gilson L,Bonnet C,Louis P,Girard C.Glucose insulin potassium infusion improves systolic function in patients with chronic ischaemic cardiomyopathy..Eur J Heart Fail2002;4:181-4

[132] Khoury VK,Prins J.Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction..Heart2003;89:61-5 PMCID:PMC1767487

[133] Demircan S,Diraman E,Kilicaslan F,Acar Z.The effect of glucose-insulin-potassium treatment on myocardial oxidative stress in patients with acute coronary syndromes undergoing percutaneous coronary intervention..Coron Artery Dis2008;19:99-104

[134] Kalay N,Gul A,Cetinkaya Y,Dogan A,Eryol NK.Effects of intermittent and long-term glucose-insulin-potassium infusion in patients with systolic heart failure..Exp Clin Cardiol2008;13:85-8 PMCID:PMC2586402

[135] Klein LJ,Sieswerda GT,Visser FC.Effects of high-dose insulin infusion on left ventricular function in normal subjects..Neth Heart J2010;18:183-9 PMCID:PMC2856866

[136] Meybohm P,Brosteanu O,Gruenewald M,Coburn M,Böning A,Roesner J,Strouhal U,Laufenberg-Feldmann R,Brandes IF,Stehr SN,Wittmann M,Meyer-Treschan T,Heringlake M,Sander M,Smul T,Schilling T,Hasenclever D.A multicenter trial of remote ischaemic preconditioning for heart surgery..N Engl J Med2015;373:1397-407

[137] Hausenloy DJ,Evans R,Jenkins DP,Knight R,Laing C,Pepper J,Xenou M,Yellon DM.Remote ischaemic preconditioning and outcomes of cardiac surgery..N Engl J Med2015;373:1408-17

[138] Przyklenk K,Ovize M,Whittaker P.Regional ischaemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion..Circulation1993;87:893-9

[139] Thielmann M,Kleinbongard P,Gedik N,Price V,Neuhäuser M,Jakob H.Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial..Lancet2013;382:597-604

[140] Hong DM,Kim HJ,Chin JH,Bahk JH,Choi IC.Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote ischaemic preconditioning with postconditioning outcome trial..Eur Heart J2014;35:176-83

[141] Sachdeva J,Gerczuk PZ.Combined remote perconditioning and postconditioning failed to attenuate infarct size and contractile dysfunction in a rat model of coronary artery occlusion..J Cardiovasc Pharmacol Ther2014;19:567-73

[142] Eitel I,Rommel KP,Sandri M,Linke A,Lurz P,Mende M,Schuler G.Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized lipsia conditioning trial..Eur Heart J2015;36:3049-57

[143] Pichot S,Bejan-Angoulvant T,Rioufol G,Boussaha I,Elbaz M,Angoulvant D.Influence of cardiovascular risk factors on infarct size and interaction with mechanical ischaemic postconditioning in ST-elevation myocardial infarction..Open Heart2015;2:e000175 PMCID:PMC4533201

[144] Moscarelli M,Suleiman S,Punjabi PP.Remote ischaemic preconditioning: is it a flag on the field?.Perfusion2015;30:438-47

[145] Kottenberg E,Thielmann M,Peters J.Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischaemic preconditioning during coronary artery bypass grafting..J Thorac Cardiovasc Surg2014;147:376-82

[146] Kleinbongard P,Thielmann M,Peters J,Heusch G.Confounders of cardioprotection by remote ischaemic preconditioning in patients undergoing coronary artery bypass grafting..Cardiology2016;133:128-33

[147] Hausenloy DJ,Yellon DM.Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent..Br J Pharmacol2012;165:1235-45 PMCID:PMC3372712

[148] Hausenloy DJ,Boston-Griffiths E,Chaubey S,Desai J.The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial..Heart2014;100:544-9 PMCID:PMC3963550

[149] Iyer A,Doyle A,Jayewardene D,Kumarasinghe G,Hicks M,Feneley MP,Graham RM,Macdonald PS.Increasing the tolerance of DCD hearts to warm ischemia by pharmacological postconditioning..Am J Transplant2014;14:1744-52

[150] Watson AJ,Sun L,Jabbour A,Jansz PC,Macdonald PS.Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution..J Heart Lung Transplant2013;32:633-40

[151] Trahanas JM,Alghanem F,Iyengar A,Hoenerhoff MJ,Bartlett RH,Owens GE.Achieving 12 hour normothermic ex situ heart perfusion: an experience of 40 porcine hearts..ASAIO J2016;62:470-6 PMCID:PMC4925299

[152] Hing AJ,Hicks M,Faddy SC,Kesteven SH,Jansz P,Macdonald PS.Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation..Am J Transplant2009;9:2048-56

[153] Gao L,Sun L,Watson A,Hicks M.Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation - the rat isolated working heart..Br J Pharmacol2011;162:633-47 PMCID:PMC3041253